Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Boston Scientific Co. (NYSE:BSX)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Boston Scientific Co. (NYSE:BSX). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on March 17th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 4/1/2025.
• Sold $1,001 - $15,000 in shares of W. R. Berkley NYSE: WRB on 4/1/2025.
• Sold $15,001 - $50,000 in shares of GoDaddy NYSE: GDDY on 4/1/2025.
• Purchased $1,001 - $15,000 in shares of Ford Motor NYSE: F on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 3/31/2025.
• Purchased $1,001 - $15,000 in shares of Boeing NYSE: BA on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Hologic NASDAQ: HOLX on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/31/2025.

Boston Scientific Trading Up 0.9 %

NYSE BSX traded up $0.85 during mid-day trading on Monday, reaching $94.52. 1,015,521 shares of the stock were exchanged, compared to its average volume of 6,336,505. The stock has a market capitalization of $139.80 billion, a PE ratio of 75.62, a PEG ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17. The business's fifty day simple moving average is $100.54 and its 200 day simple moving average is $94.10.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Mechanics Bank Trust Department bought a new position in shares of Boston Scientific in the fourth quarter worth about $415,000. Highland Capital Management LLC bought a new stake in Boston Scientific in the 4th quarter valued at $4,887,000. Covenant Asset Management LLC bought a new position in shares of Boston Scientific during the 4th quarter worth about $3,405,000. Brookstone Capital Management lifted its stake in shares of Boston Scientific by 23.7% in the fourth quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock valued at $9,455,000 after buying an additional 20,307 shares during the period. Finally, Beacon Investment Advisory Services Inc. grew its position in Boston Scientific by 31.7% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock worth $1,744,000 after buying an additional 4,702 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Royal Bank of Canada upped their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Truist Financial lowered their price objective on Boston Scientific from $120.00 to $113.00 and set a "buy" rating for the company in a research note on Friday. Stifel Nicolaus raised their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Finally, Argus set a $130.00 target price on Boston Scientific in a report on Tuesday, February 18th. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $109.04.

Insider Activity at Boston Scientific

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of Boston Scientific stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the sale, the executive vice president now directly owns 5,502 shares of the company's stock, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is owned by corporate insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.